代谢紊乱及其后遗症的临床分期指导管理:欧洲动脉粥样硬化学会共识声明
欧洲动脉粥样硬化学会提出基于病理生理学的系统代谢紊乱(SMD)三阶段分期:1期代谢异常无器官损害,2期早期器官损害(2型糖尿病、无症状舒张功能障碍、MASH、CKD),3期多器官晚期损害。高危肥胖是最常见病因,管理包括生活方式、药物和代谢手术。
要点
- SMD分为3期:1期代谢异常无器官损害,2期早期器官损害,3期多器官晚期损害。
- 高危肥胖是SMD最常见病因,导致异位脂质积累和胰岛素抵抗。
- 管理包括生活方式改变、药物治疗,严重病例可行代谢手术。
核心结论
- SMD三阶段分期系统有助于理解其多系统特性并推动个体化全局治疗,以减轻肥胖相关共病负担。
研究设计与样本
- 欧洲动脉粥样硬化学会发布的共识声明,提出基于病理生理学的SMD三阶段分期系统。
主要发现
- SMD 1期为代谢异常(如功能障碍性肥胖和血脂异常)无 detectable 器官损害。
- SMD 2期表现为早期器官损害,包括2型糖尿病、无症状舒张功能障碍、MASH和CKD。
- SMD 3期以多器官晚期损害为特征。
- 高危肥胖由持续正能量平衡驱动,是SMD最常见原因,导致异位脂质积累和胰岛素抵抗。
- 遗传因素影响SMD易感性,民族差异归因于遗传和社会经济因素。
关键数值与推荐
- SMD关键特征包括胰岛素抵抗、炎症、糖尿病前期、2型糖尿病、MASH、高血压、CKD、致动脉粥样硬化性血脂异常和心力衰竭。
临床怎么用
- 根据SMD分期(1-3期)评估患者器官损害程度,指导生活方式、药物和代谢手术等分层管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obesity rates have surged since 1990 worldwide. This rise is paralleled by increases in pathological processes affecting organs such as the heart, liver, and kidneys, here termed systemic metabolic disorders (SMDs). For clinical management of SMD, the European Atherosclerosis Society proposes a pathophysiology-based system comprising three stages: Stage 1, where metabolic abnormalities such as dysfunctional adiposity and dyslipidaemia occur without detectable organ damage; Stage 2, which involves early organ damage manifested as Type 2 diabetes, asymptomatic diastolic dysfunction, metabolic-associated steatohepatitis (MASH), and chronic kidney disease (CKD); and Stage 3, characterized by more advanced organ damage affecting multiple organs. Various forms of high-risk obesity, driven by maintained positive energy balance, are the most common cause of SMD, leading to ectopic lipid accumulation and insulin resistance. This progression affects various organs, promoting comorbidities such as hypertension and atherogenic dyslipidaemia. Genetic factors influence SMD susceptibility, and ethnic disparities in SMD are attributable to genetic and socioeconomic factors. Key SMD features include insulin resistance, inflammation, pre-diabetes, Type 2 diabetes, MASH, hypertension, CKD, atherogenic dyslipidaemia, and heart failure. Management strategies involve lifestyle changes, pharmacotherapy, and metabolic surgery in severe cases, with emerging treatments focusing on genetic approaches. The staging system provides a structured approach to understanding and addressing the multi-faceted nature of SMD, which is crucial for improving health outcomes. Categorization of SMD abnormalities by presence and progression is aimed to improve awareness of a multi-system trait and encourage a tailored and global approach to treatment, ultimately aiming to reduce the burden of obesity-related comorbidities.
引用
- Romeo S, Vidal-Puig A, Husain M, et al. Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement. Eur Heart J. 2025. PMID: 40331343. doi:10.1093/eurheartj/ehaf314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。